I-125 brachytherapy for prostate cancer linked to small increase in bladder cancer risk

Second primary malignancies affected 10.8% of men who received I-125 brachytherapy as monotherapy for prostate cancer, researchers reported in the April issue of Clinical Oncology.

But only bladder...